Premium Company Profile Aspreva Pharmaceuticals Corporation

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Databook
Pages	39
ISBN Number	not applicable
Product Code	DAT08351

Price

£265.00
approximately: $468 | €336

PRINT £265 ($468 | €336)

Order above formats by FAX

Summary

Introduction

Aspreva is a pharmaceutical company involved in identifying, developing and commercializing drugs and drug candidates for the treatment of less common diseases. Aspreva has worldwide rights, excluding Japan, to develop and commercialize Roche's CellCept (mycophenolate mofetil) for all autoimmune indications.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Aspreva is focused on the development and commercialization of CellCept for autoimmune indications. The company develops CellCept for the indications such as Lupus nephritis, multiple sclerosis, pemphigus vulgaris, and scleroderma/systemic sclerosis. CellCept is under various stages of drug development process for the above said indications.

Aspreva derives its revenues from royalties received from its collaborative agreement with Roche. The company started recording revenues from fiscal 2005 only. Its total revenues increased from $76 million in 2005 and $215 million in 2006, representing an absolute total growth of +$139 million during 2005-2006.

The company is forecast to derive all of its revenues from CellCept royalties. The company's revenues are forecast to grow at a CAGR of 9% during 2006-2010, from $215 million to $304 million 2010. This represents an absolute growth of +$89 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Collaboration Pipeline
- CellCept
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Increasing investments in R&D
- Inclusion of experienced professionals in the management team
- Weaknesses
- over dependence on sole development partner
- Opportunities
- Merger with Galenica
- Malaysian approval of CellCept for lupus nephritis
- Threats
- CellCept patent expiration
- Regulatory hurdles
- Cost containment measures
- Value Chain Analysis
- Overview
- Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- J William Freytag
- Noel Hall
- Kirk K Calhoun
- Richard M Glickman
- Julia G Levy
- George M Milne
- Arnold L Oronsky
- William Hunter
- Bruce Cousins
- Usman Azam
- Rick Goulburn
- Paul Brennan
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
List of Tables
- Table 1: Aspreva Pharmaceuticals - Key Facts
- Table 2: Aspreva Pharmaceuticals - Locations and Subsidiaries
- Table 3: Aspreva Pharmaceuticals - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: Aspreva Pharmaceuticals - Key Events Impacting Share Price Performance
- Table 5: Aspreva Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Aspreva Pharmaceuticals - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 7: Aspreva Pharmaceuticals - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Aspreva Pharmaceuticals - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Aspreva Pharmaceuticals - Collaboration Products
- Table 10: Aspreva Pharmaceuticals - Historical Product Sales, 2002-2006 ($ Mn)
- Table 11: Aspreva Pharmaceuticals - Forecast Sales, 2006-2010 ($ Mn)
- Table 12: Aspreva Pharmaceuticals - Key Competitors
- Table 13: Aspreva Pharmaceuticals - Key Suppliers
- Table 14: Aspreva Pharmaceuticals - Key Shareholders
- Table 15: Aspreva Pharmaceuticals - SWOT Analysis Summary
- Table 16: Aspreva Pharmaceuticals - Value Chain Analysis
- Table 17: Aspreva Pharmaceuticals - Scorecard
- Table 18: Aspreva Pharmaceuticals - Key Employees
- Table 19: Aspreva Pharmaceuticals - Financial and Operational Overview
List of Figures
- Figure 1: Aspreva Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)